| Citation: |
SHEN Wenwen, LIU Qin, HUANG Kai, JIANG Xiaogan, CHEN Shanghua. Value of plasma the soluble CD14 subtype in early diagnosis of sepsis patients with acute renal injury[J]. Journal of Clinical Medicine in Practice, 2024, 28(10): 46-50. DOI: 10.7619/jcmp.20232835
|
To evaluate the diagnostic value of plasma the soluble CD14 subtype (sCD14-ST, renamed as presepsin) in early diagnosis of sepsis patients with acute kidney injury (AKI).
A total of 110 patients with AKI in intensive care unit(ICU)of Wuhu Hospital Affiliated to East China Normal University from January 2021 to December 2022 were prospectively selected. The patients were divided into AKI stage 1 group (n=34), AKI stage 2 group (n=36) and AKI stage 3 group (n=40) according to the staging criteria defined byKidney Disease: Improving Global Outcomes (KDIGO) in 2012, and 53 non-AKI patients in the same period were selected as the control group. The patients were further divided into non-sepsis group and sepsis group according to whether combined sepsis or not. Plasma Presepsin levels were recorded in all the patients. Receiver operating characteristic (ROC) curve was drawn to evaluate the diagnostic value of Presepsin inearly sepsis in AKI patients, and the optimal cutoff value was found using Jorden index.
The level of Presepsin in the sepsis group was higher than that in non-sepsis group (P < 0.05). In non-sepsis patients, the level of Presepsin increased gradually with the aggravation of renal function injury (P < 0.05). The level of Presepsin in stage 3 AKI group was higher than that in non-AKI group (P < 0.01). ROC curve analysis results showed that thearea under the curve (AUC) of Presepsin level for diagnosing sepsis in stage 1 AKI group, stage 2 AKI group and stage 3 AKI group was smaller than that in non-AKI group (P > 0.05).
Presepsin can be used as a marker for early diagnosis of sepsis in AKI patients, but different thresholds should be used according to the severity of renal impairment.
| [1] |
SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. doi: 10.1001/jama.2016.0287
|
| [2] |
TAMBO M, TAGUCHI S, NAKAMURA Y, et al. Presepsin and procalcitonin as predictors of sepsis based on the new Sepsis-3 definitions in obstructive acute pyelonephritis[J]. BMC Urol, 2020, 20(1): 23. doi: 10.1186/s12894-020-00596-4
|
| [3] |
KELLUM J A, LAMEIRE N, ASPELIN P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury[J]. Kidney Int Suppl, 2012, 2(1): 1-138. doi: 10.1038/kisup.2012.1
|
| [4] |
RHODES A, EVANS L E, ALHAZZANI W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016[J]. Intensive Care Med, 2017, 43(3): 304-377. doi: 10.1007/s00134-017-4683-6
|
| [5] |
潘玉静, 张路霞. 估算肾小球滤过率的评价方法[J]. 中华内科杂志, 2016, 55(3): 237-240.
|
| [6] |
MANRIQUE-CABALLERO C L, DEL RIO-PERTUZ G, GOMEZ H. Sepsis-Associated Acute Kidney Injury[J]. Crit Care Clin, 2021, 37(2): 279-301. doi: 10.1016/j.ccc.2020.11.010
|
| [7] |
LABRO G, APTEL F, PUYRAVEAU M, et al. Impact on antimicrobial consumption of procalcitonin-guided antibiotic therapy for pneumonia/pneumonitis associated with aspiration in comatose mechanically ventilated patients: a multicenter, randomized controlled study[J]. Ann Intensive Care, 2021, 11(1): 145. doi: 10.1186/s13613-021-00931-4
|
| [8] |
DZIARSKI R, TAPPING R I, TOBIAS P S. Binding of bacteri al peptidoglycan to CD14[J]. J Biol Chem, 1998, 273(15): 8680-8690. doi: 10.1074/jbc.273.15.8680
|
| [9] |
SHIRAKAWA K, NAITOU K, HIROSE J, et al. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models[J]. Crit Care, 2010, 14(Suppl 2): 19. doi: 10.1186/cc9122
|
| [10] |
HASSAN E A, ABDEL REHIM A S, AHMED A O, et al. Clinical Value of Presepsin in Comparison to hsCRP as a Monitoring and Early Prognostic Marker for Sepsis in Critically Ⅲ Patients[J]. Medicina (Kaunas, Lithuania), 2019, 55(2): 1-11.
|
| [11] |
KOIZUMI Y, SAKANASHI D, MOHRI T, et al. Can Presepsin uniformly respond to various pathogens- an in vitro assay of new sepsis marker[J]. BMC Immunol, 2020, 21(1): 33. doi: 10.1186/s12865-020-00362-z
|
| [12] |
NAKAMURA Y, ISHIKURA H, NISHIDA T, et al. Usefulness of Presepsin in the diagnosis of sepsis in patients with or without acute kidney injury[J]. BMC Anesthesiol, 2014, 14: 88. doi: 10.1186/1471-2253-14-88
|
| [13] |
HAN S, KIM M J, KO H J, et al. Diagnostic and Prognostic Roles of C-Reactive Protein, Procalcitonin, and Presepsin in Acute Kidney Injury Patients Initiating Continuous Renal Replacement Therapy[J]. Diagnostics (Basel), 2023, 13(4): 777. doi: 10.3390/diagnostics13040777
|
| [14] |
奚希相, 李文放, 马金苗, 等. 尿NGAL联合MEDS评分评估脓毒症合并急性肾损伤患者病情及预后[J]. 第二军医大学学报, 2017, 38(2): 244-248. https://www.cnki.com.cn/Article/CJFDTOTAL-DEJD201702020.htm
|
| [15] |
TAKAHASHI G, SHIBATA S, FUKUI, et al. Diagnostic accuracy of procalcitonin and presepsin for infectious disease in patients with acute kidney injury[J]. Diagn Microbiol Infect Dis, 2016, 86(2): 205-210. doi: 10.1016/j.diagmicrobio.2016.07.015
|
| [16] |
NAKAMURA Y, MURAI A, MIZUNUMA M, et al. Potential use of procalcitonin as biomarker for bacterial sepsis in patients with or without acute kidney injury[J]. J Infect Chemother, 2015, 21(4): 257-263. doi: 10.1016/j.jiac.2014.12.001
|
| [17] |
NAKAMURA Y, HOSHINO K, KIYOMI F, et al. Comparison of accuracy of presepsin and procalcitonin concentrations in diagnosing sepsis in patients with and without acute kidney injury[J]. Clin Chim Acta, 2019, 490: 200-206. doi: 10.1016/j.cca.2018.09.013
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: